



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/723,374	11/25/2003	Mel Kronick	10031014-1	8009
22878 7590 12/22/2006 AGILENT TECHNOLOGIES INC. INTELLECTUAL PROPERTY ADMINISTRATION, M/S DU404 P.O. BOX 7599 LOVELAND, CO 80537-0599			EXAMINER CALAMITA, HEATHER	
			ART UNIT	PAPER NUMBER
			1637	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		12/22/2006	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

<b>Office Action Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	10/723,374		KRONICK ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Heather G. Calamita, Ph.D.		1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 10 October 2006.
- 2a) ☒ This action is FINAL.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-35 is/are pending in the application.
- 4a) Of the above claim(s) 11 and 17-35 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-10 and 12-16 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

## DETAILED ACTION

### *Status of Application, Amendments, and/or Claims*

1. Amendments of October 10, 2006, have been received and entered in full. Claims 1-35 are pending. Claims 1-10 and 12-16 are under examination. Claims 11 and 17-35 are withdrawn as directed to non-elected subject matter. All arguments have been fully considered and thoroughly reviewed, but are deemed not persuasive for the reasons that follow. Any objections and rejections not reiterated below are hereby withdrawn.

### *Claim Rejections - 35 USC § 102*

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-10 and 12-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Albitar et al. (Molecular Diagnosis, 1997).

With regard to claim 1, Albitar et al. teach a method of producing a biopolymeric array comprising immobilizing at least a first population of a number of copies of a first probe for a first target to a surface of a solid support, wherein said number of said first population is dependant on the at least anticipated abundance of said target in a sample for which said array is designed to assay (see p.172 col. 2 under Simplified RDB Assay, where the first population of probes are the probes for codons 12, 13 and 61 and the probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol as the target is anticipated to fall within one of these concentrations).

With regard to claim 2, Albitar et al. teach at least first population is present in at least one feature at a probe density that is in the range of about .001 pmoles/mm<sup>2</sup> to about 10 pmoles/mm<sup>2</sup> (see p.172 col. 2

Art Unit: 1637

under Simplified RDB Assay and Figure 1, where the probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol all of which fall within the recited concentration range. The length of the spot is 6.35 mm and the width is 2.5 mm the density of the 15 pmol spot is 0.94 pmol, the density of the 75 pmol spot is 4.7 pmol and the density of the 375 pmol spot is 24 pmol).

With regard to claim 3, Albitar et al. teach at least first population is present in at least two replicate features (see p.173 Figure 1, where each of the probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol or 3 replicates which meets the limitation of at least 2 replicates).

With regard to claim 4, Albitar et al. teach each of said replicate features comprises probes at a density that ranges from about .001 pmoles/mm<sup>2</sup> to about 10 pmoles/mm<sup>2</sup> (see p.172 col. 2 under Simplified RDB Assay and Figure 1, where each of the probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol all of which fall within the recited concentration range. The length of the spot is 6.35 mm and the width is 2.5 mm the density of the 15 pmol spot is 0.94 pmol, the density of the 75 pmol spot is 4.7 pmol and the density of the 375 pmol spot is 24 pmol).

With regard to claim 5, Albitar et al. teach the number of probe copies of said at least first population ranges from about  $6 \times 10^4$  probes/feature to about  $6 \times 10^{12}$  probes/feature (see p.172 col. 2 under Simplified RDB Assay and Figure 1, where each of the probes are immobilized onto the membrane in different concentrations (15, 75 and 375 pmol) and 15 pmol is equivalent to  $9.0 \times 10^{11}$  and 75 pmol is equivalent to  $4.51 \times 10^{12}$  both of which fall within the recited concentration range).

With regard to claim 6, Albitar et al. teach the number of probe copies of said at least first population is chosen so as to provide a particular signal to noise ratio for an array assay using said biopolymeric array (see p.172 col. 1 under Simplified RDB Assay, where each of the probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol these concentrations are chosen to determine if the signal is linear i.e. optimize the signal with respect to noise).

Art Unit: 1637

With regard to claim 7, Albitar et al. teach performing a first assay with said sample to determine said at least anticipated abundance of said target (see p. 174 Figure 2 and p. 171 Table 1, where the assay was performed to determine the abundance of the target, i.e. its presence or absence).

With regard to claim 8, Albitar et al. teach the first assay is performed with an array (see p. 174 Figure 2 and p. 171 Table 1, where the dot blot meets the limitation of an array).

With regard to claim 9, Albitar et al. teach the array is a genome-wide array (see p. 172 col. 2 under Simplified RDB Assay 2<sup>nd</sup> full paragraph, where the DNA is extracted from peripheral blood samples, therefore the DNA hybridized is genomic DNA making the array a genome wide array).

With regard to claim 10, Albitar et al. teach the probe copies are nucleic acids (see p. 172 col. 2 under Simplified RDB Assay 1<sup>st</sup> full paragraph, where the probes are 20-base oligonucleotides).

With regard to claim 12, Albitar et al. teach the method further comprises immobilizing at least a second population of a number of copies of a second probe for a second target, wherein said number of probe copies of said second population is dependant on the at least anticipated abundance of said second target in said sample for which said array is desired to assay (see p. 173 Figures 1 and p. 174 Figure 2, where multiple populations of oligonucleotide probes are immobilized).

With regard to claim 13, Albitar et al. teach the first target is at least suspected of being present in a higher abundance than said second target in said sample and said number of probe copies of said first population is less than the number of probe copies of said second population (see Figure 1, where each of the populations of probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol where the WT is expected to be present i.e. in greater abundance than the other targets).

With regard to claim 14, Albitar et al. teach the first target is at least suspected of being present in a higher abundance than said second target in said sample and said density of said first population is less than the density of said second population (see Figure 1, where each of the populations of probes are

Art Unit: 1637

immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol where the WT is expected to be present i.e. in greater abundance than the other targets).

With regard to claim 15, Albitar et al. teach a method of preparing a biopolymeric array, said method comprising:

(a) determining the relative abundance of targets in a sample type for which said array is desired to be used (see p. 174 Figure 2 and p. 171 Table 1, where the assay was performed to determine the abundance of the target, i.e. its presence or absence); and

(b) immobilizing populations of different probes for respective targets at relative numbers which are dependent upon the relative abundance of said targets (see p. 174 Figure 2, p. 173 Figure 1 and p. 171 Table 1, where the populations of probes were immobilized in different concentrations and used to determine the abundance of the target, i.e. its presence or absence).

With regard to claim 16, Albitar et al. teach a method of preparing a biopolymeric array, said method comprising:

(a) determining the relative abundance of targets in a sample type for which said array is desired to be used ((see p. 174 Figure 2 and p. 171 Table 1, where the assay was performed to determine the abundance of the target, i.e. its presence or absence); and

(b) immobilizing populations of different probes for respective targets at relative total feature areas which are dependent upon the relative abundance of said targets (see p. 174 Figure 2, p. 173 Figure 1 and p. 171 Table 1, where the populations of probes were immobilized in different concentrations and used to determine the abundance of the target, i.e. its presence or absence).

### *Response to Arguments*

5. Applicants' arguments filed October 10, 2006, have been fully considered but they are not persuasive.

Art Unit: 1637

With respect to the 102 (b) rejections of claims 1-10, and 12-16, applicants argue Albitar does not teach the density of the probes of a feature is dependent on the anticipated abundance of target for that probe in a sample. This argument is not persuasive because as outlined in the rejection above, Albitar teaches making a dot blot comprising features containing three different probe densities within the claimed range (see p.172 col. 2 under Simplified RDB Assay and Figure 1, where the probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol all of which fall within the recited concentration range. The length of the spot is 6.35 mm and the width is 2.5 mm the density of the 15 pmol spot is 0.94 pmol, the density of the 75 pmol spot is 4.7 pmol and the density of the 375 pmol spot is 24 pmol). Applicant argues Albitar does not base the probe density at each feature on the abundance of the expected target. This argument is not persuasive because Albitar places the probes in anticipation of the abundance of target see for example Figure 1, where each of the populations of probes are immobilized onto the membrane in 3 different concentrations 15, 75 and 375 pmol where the WT is expected to be present i.e. in greater abundance than the other targets. For these reasons the rejections are maintained.

### *Conclusion*

6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1637

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

***Correspondence***

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Heather G. Calamita whose telephone number is 571.272.2876 and whose e-mail address is heather.calamita@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner can normally be reached on Monday through Thursday, 7:00 AM to 5:30 PM.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at 571.272.0782.

Papers related to this application may be faxed to Group 1637 via the PTO Fax Center using the fax number 571.273.8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to 571.272.0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

hgc

TERESA E. STRZELECKA, PH.D.  
PRIMARY EXAMINER

*Teresa Strzelecka*  
12/18/06